AOD-9604: The Growth Hormone Fragment Targeting Fat Metabolism

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH). It consists of amino acids 177-191 of the hGH molecule with a tyrosine residue added at position 177. This 16-amino-acid peptide was developed by Professor Frank Ng at Monash University in Melbourne, Australia.

The idea was that the fat-metabolizing activity of growth hormone could be isolated from its growth-promoting and insulin-opposing effects.

The rationale stems from a critical finding in endocrinology: full-length growth hormone (191 amino acids) promotes both fat breakdown (lipolysis) and longitudinal growth. It also causes insulin resistance and may stimulate tumor growth through IGF-1 elevation.

These effects make chronic GH dosing problematic for weight management. AOD-9604 was designed to keep only the fat-breakdown domain, cutting the 176 amino acids that cause growth and metabolic disruption.

Development began in the 1990s at Monash University. It progressed through preclinical studies showing fat-reducing effects without growth-promoting activity. It then advanced to human clinical trials. In 2010, AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA as a food ingredient — an unusual regulatory path for a synthetic peptide fragment.

This history sets AOD-9604 apart from most research peptides, which lack any formal safety designation. For context on how peptide fragments relate to parent molecules, see our complete peptide guide. For repair-focused vs fat-focused compounds, read BPC-157 vs AOD-9604.

AOD-9604's action centers on stimulating fat breakdown (lipolysis) and blocking fat formation (lipogenesis) in adipose tissue. It does this without activating the growth hormone receptor's growth-promoting pathways.

Lipolytic Activity: AOD-9604 stimulates beta-3 adrenergic receptor-mediated lipolysis in fat cells. In vitro studies using human and animal adipose tissue show that AOD-9604 raises hormone-sensitive lipase (HSL) activity.

HSL is the enzyme that breaks stored triglycerides into free fatty acids and glycerol for energy use. This effect is concentration-dependent. Maximal activity was seen at 10-100 nM concentrations in cell culture.

Anti-Lipogenic Activity: Beyond breaking down existing fat, AOD-9604 blocks formation of new fat. It lowers fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) — the key enzymes in new fat creation. Preclinical studies show a 30-40% reduction in these enzymes in treated fat tissue versus controls. This suggests AOD-9604 creates conditions favoring net fat loss.

No Growth-Promoting Effects: Critically, AOD-9604 does not activate the JAK2-STAT5 signaling pathway behind GH's growth effects. It does not raise IGF-1 levels. It does not stimulate bone growth. It does not cause the insulin resistance linked to full-length GH dosing.

In preclinical studies, AOD-9604 produced no changes in serum IGF-1, insulin, or glucose at doses that greatly reduced fat mass.

Cartilage-Protective Properties: An unexpected finding is AOD-9604's cartilage-protective activity. Studies in Journal of Molecular Endocrinology showed it stimulates proteoglycan production in joint cartilage and blocks matrix metalloproteinase (MMP) activity that degrades cartilage.

This has led to research on AOD-9604 for osteoarthritis — a use distinct from its original fat loss purpose. For more on fat-metabolizing peptides, see our weight management peptide guide.

AOD-9604 has progressed further through clinical development than many research peptides. Phase IIb human trial data is available.

Phase IIb Clinical Trial: A randomized, double-blind, placebo-controlled trial enrolled 300 obese adults (BMI 35-40). They received oral AOD-9604 at 1 mg, 5 mg, 10 mg, or 20 mg daily — or placebo — for 24 weeks. The primary endpoint was change in body weight.

Results showed a dose-dependent trend in weight reduction. The highest dose group (20 mg oral daily) showed a mean weight loss of about 2.8 kg versus 0.8 kg for placebo. This was statistically significant but clinically modest.

Safety Data: Across the trial, AOD-9604 was well-tolerated. No major adverse events were linked to treatment. Critically, there were no changes in fasting glucose, insulin, IGF-1, or HbA1c. This confirms that AOD-9604 does not cause the metabolic disruptions linked to full-length GH. Liver function, renal function, and blood parameters stayed normal throughout the 24-week study.

Limitations of Clinical Data: While the trial confirmed safety and showed statistical significance, the weight loss size (about 2 kg net difference versus placebo over 24 weeks) was deemed too small for regulatory approval as an anti-obesity drug.

For comparison, semaglutide produces 12-16% body weight reduction over similar timeframes. This modest effectiveness led the developing company (Metabolic Pharmaceuticals) to discontinue the obesity program. The safety profile was considered favorable.

Route of Dosing Factor: The Phase IIb trial used oral AOD-9604, which has much lower bioavailability than subcutaneous injection. Research protocols using injectable AOD-9604 suggest potentially greater effects at lower doses.

However, controlled trials comparing oral and injectable routes have not been published. The oral bioavailability of peptides is generally less than 1-2%. The effective systemic dose from oral dosing may have been a fraction of the labeled dose.

AOD-9604 dosing varies greatly between oral and injectable routes. This reflects the bioavailability difference. All dosing info is for research reference only.

Subcutaneous Injection

Research protocols typically use 250-300 mcg subcutaneously once daily in the morning on an empty stomach. Some protocols use a loading phase of 400-500 mcg daily for 2 weeks before reducing to 250-300 mcg for maintenance. Injection is typically in the abdominal subcutaneous fat.

Morning fasted dosing is preferred. Insulin — elevated in the fed state — opposes fat-breakdown activity.

Oral Dosing

The Phase IIb trial used oral doses of 1-20 mg daily. For oral research, doses of 10-20 mg daily on an empty stomach reflect the clinical trial protocol. Oral dosing must be on a fully empty stomach (overnight fast) with water only. Food dramatically reduces the already-low oral bioavailability of peptide fragments.

Research Protocol Duration

Research protocols typically run 8-12 weeks for initial assessments. The Phase IIb trial ran 24 weeks. AOD-9604 does not appear to require cycling — no receptor desensitization has been documented at standard doses. Continuous administration throughout the research period is the standard approach.

Reconstitution

For injectable preparations, reconstitute lyophilized AOD-9604 with bacteriostatic water. A 5 mg vial reconstituted with 2 mL gives a concentration of 2,500 mcg/mL. For a 250 mcg dose, draw 10 units on a U-100 insulin syringe. Store reconstituted solution refrigerated at 2-8°C and use within 4-6 weeks. Use our peptide calculator for precise reconstitution calculations.

Placing AOD-9604 in context with other fat-metabolizing compounds helps researchers evaluate its role in body composition research.

AOD-9604 vs. HGH Fragment 176-191: These terms are sometimes used interchangeably, but there is a difference. HGH Fragment 176-191 is the unmodified C-terminal fragment of growth hormone. AOD-9604 is the same fragment with an added tyrosine residue at position 177.

This boosts stability and fat-breakdown potency. In research, AOD-9604 is generally preferred due to its greater stability and more extensive documentation.

AOD-9604 vs. Tesamorelin: Tesamorelin stimulates natural GH release, producing broad GH effects including fat loss, muscle support, and IGF-1 elevation. AOD-9604 provides only the fat-breakdown component without GH release or IGF-1 elevation.

Tesamorelin has stronger clinical evidence (FDA-approved, Phase III data showing 15-18% VAT reduction). AOD-9604 has a narrower but potentially safer pathway for cases where IGF-1 elevation is undesirable. See our tesamorelin research guide for comparison.

AOD-9604 vs. Semaglutide/Tirzepatide: GLP-1 agonists produce dramatically greater weight loss (12-21% of body weight) versus AOD-9604 (about 2.8 kg absolute in clinical trials). However, GLP-1 agonists achieve this partly through appetite suppression and GI slowing.

Major nausea is a common side effect. AOD-9604's pathway is purely fat-breakdown-focused with no appetite effects. This may make it useful as an addition in combination protocols or for subjects who do not respond to GLP-1 agonists.

AOD-9604 vs. CJC-1295/Ipamorelin: GH secretagogue stacks raise natural GH. This produces fat breakdown alongside muscle growth, improved sleep, and cognitive effects. AOD-9604 isolates the fat-breakdown component.

The broader effects of GH secretagogues may be better when body recomposition (simultaneous fat loss and muscle gain) is the goal.

AOD-9604's targeted pathway may be better when pure fat loss without GH-axis stimulation is desired. Research listings (education hub—not a lab).

AOD-9604's regulatory status is unusual among research peptides and deserves specific attention.

FDA GRAS Designation: In 2010, AOD-9604 received Generally Recognized as Safe (GRAS) status from the FDA as a food ingredient. This was based on safety data from the Phase IIb trial and supporting preclinical studies.

GRAS status means the FDA acknowledges AOD-9604's safety for oral use at specified doses — a rare designation for a synthetic peptide fragment. However, GRAS status is not FDA approval as a drug. AOD-9604 cannot be marketed with therapeutic claims.

Distinction from Drug Approval: GRAS status allows AOD-9604's inclusion in food products without pre-market approval. But it does not authorize sale as a drug or dietary supplement with anti-obesity claims. Companies marketing AOD-9604 with fat-loss claims are technically violating FDA regulations unless they pursue formal drug approval. This regulatory gray area has led to varying enforcement approaches.

WADA Status: The World Anti-Doping Agency (WADA) banned AOD-9604 in 2013 as a "growth hormone releasing factor" under Section S2. This ban made headlines when AOD-9604 was linked to several sports doping cases. For researchers in athletic or sports science contexts, this WADA classification matters.

Australian Regulatory History: As an Australian-developed compound, AOD-9604 has a unique regulatory history in Australia. The Therapeutic Goods Administration (TGA) briefly approved it for a specific clinical trial application. However, the TGA has not granted marketing approval. The TGA concluded that while safety was shown, effectiveness was too limited for regulatory approval as an anti-obesity drug in Australia.

For broader context on peptide regulation, see our peptide legality guide.

AOD-9604's safety profile is among the best-documented in the research peptide category. It benefits from formal clinical trial data and GRAS assessment.

Clinical Safety Data: The Phase IIb trial with 300 participants over 24 weeks reported no serious adverse events from AOD-9604 at any dose level (1-20 mg oral daily).

Common side effects were headache, nasopharyngitis, and upper respiratory tract infection — all at rates similar to placebo. No injection site reactions were reported in the oral trial.

Subcutaneous injection studies in smaller groups report mild, brief injection site redness in about 5% of subjects.

Metabolic Safety: The key safety advantage of AOD-9604 over full-length GH is confirmed by clinical data.

There were no changes in fasting glucose (mean change <1 mg/dL), fasting insulin, HbA1c, or IGF-1 levels. This confirms the fat-breakdown fragment does not carry the insulin-opposing or growth-promoting effects of intact GH. For diabetic or pre-diabetic research subjects, this metabolic neutrality matters greatly.

Cancer Risk: Because AOD-9604 does not raise IGF-1, the theoretical cancer risk linked to chronic GH dosing (through IGF-1-driven cell growth) does not apply. No preclinical cancer risk has been reported. The GRAS safety assessment included review of this endpoint.

Drug Interactions: No major drug interactions have been documented. However, concurrent use of insulin or oral blood sugar medications should be monitored. AOD-9604's fat-breakdown activity releases free fatty acids that can briefly affect insulin sensitivity. Thyroid medications should also be watched, since fat metabolism depends on thyroid function. AOD-9604's effects may interact with thyroid-mediated metabolic control.

Quality Sourcing: Research-grade AOD-9604 should meet ≥98% HPLC purity. Mass spectrometry should confirm the correct 16-amino-acid sequence plus the N-terminal tyrosine change. Batch-specific COAs are essential—request them from the seller. About explains our editorial criteria; we don’t run QA on batches.

AOD-9604's targeted fat-breakdown pathway makes it a logical part of multi-compound research protocols.

AOD-9604 + GH Secretagogue Stack: Combining AOD-9604 with ipamorelin or CJC-1295 provides both direct fat-breakdown stimulation (AOD-9604) and GH-mediated body recomposition effects (muscle preservation, sleep improvement, recovery). The GH secretagogue provides the anabolic environment. AOD-9604 adds dedicated fat-metabolizing activity beyond what natural GH alone produces.

AOD-9604 + BPC-157 (Joint Health Protocol): Given AOD-9604's unexpected cartilage-protective properties and BPC-157's tissue repair pathways, this combination has gained attention in joint health research. AOD-9604's proteoglycan production boost combined with BPC-157's blood vessel growth and growth factor activity could address both cartilage regrowth and surrounding tissue healing in osteoarthritis models.

AOD-9604 + Lipo-C: Lipotropic compounds (methionine, inositol, choline, B12) support liver fat processing and methylation. This complements AOD-9604's fat-cell-level fat breakdown. The combination addresses fat metabolism at both the tissue level (AOD-9604) and the liver processing level (Lipo-C). See our Lipo-C guide for details.

Future Research Directions: Several promising avenues remain for AOD-9604:

• Injectable vs. oral bioavailability comparison studies — to determine if modest clinical results reflected poor oral bioavailability rather than limited effects
• Combination trials with appetite-reducing compounds — to test whether adding AOD-9604's fat-breakdown action produces additive fat loss
• Osteoarthritis applications — a potentially valuable second use, given the existing cartilage-protective data and large unmet need
• Long-acting formulations using sustained-release depot technologies — enabling weekly dosing and improving adherence

For related fat-loss research compounds, explore our tirzepatide and cagrilintide guides.